Eugene Schneider insider trades: Ionis Pharmaceuticals (IONS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Eugene reports to the SEC
Open-market buys and sales
14 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | IONS | ↓ Sell10b5-1 | 26,000 | $81.05 | $2.1M | Direct | Jun 30, 2026 (4d) |
| Mar 19, 2026 | IONS | ↓ Sell10b5-1 | 5,812 | $70.97 | $412K | Direct | Mar 23, 2026 (4d) |
| Jan 30, 2026 | IONS | ↓ Sell | 6,179 | $83.45 | $516K | Direct | Feb 2, 2026 (3d) |
| Jan 16, 2026 | IONS | ↓ Sell | 9,302 | $75.59 | $703K | Direct | Jan 20, 2026 (4d) |
| Sep 3, 2025 | IONS | ↓ Sell10b5-1 | 19,658 | $60.81 | $1.2M | Direct | Sep 4, 2025 (1d) |
| Aug 4, 2025 | IONS | ↓ Sell10b5-1 | 9,549 | $42.80 | $409K | Direct | Aug 5, 2025 (1d) |
| Jan 31, 2025 | IONS | ↓ Sell | 1,484 | $32.20 | $48K | Direct | Feb 3, 2025 (3d) |
| Jan 16, 2025 | IONS | ↓ Sell | 6,523 | $32.79 | $214K | Direct | Jan 17, 2025 (1d) |
| Feb 2, 2024 | IONS | ↓ Sell | 2,071 | $49.59 | $103K | Direct | Feb 2, 2024 (0d) |
| Jan 17, 2024 | IONS | ↓ Sell | 5,482 | $50.42 | $276K | Direct | Jan 18, 2024 (1d) |
| Jan 12, 2024 | IONS | ↓ Sell | 8,000 | $53.50 | $428K | Direct | Jan 17, 2024 (5d) |
| Dec 26, 2023 | IONS | ↓ Sell | 25,000 | $51.46 | $1.3M | Direct | Dec 28, 2023 (2d) |
| Feb 6, 2023 | IONS | ↓ Sell | 1,413 | $40.67 | $57K | Direct | Feb 7, 2023 (1d) |
| Jan 18, 2023 | IONS | ↓ Sell | 4,752 | $39.57 | $188K | Direct | Jan 19, 2023 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other IONS insiders
Open-market trades in the last 12 months
About Eugene Schneider's insider trades
Eugene Schneider is EVP, Chf Clinical Develop Ofcr at Ionis Pharmaceuticals (IONS). Since Jan 18, 2023, Eugene has reported no open-market purchases and 14 sales worth $7.9M on SEC Form 4. In the last 12 months: 4 sales ($3.7M).
4 sales (52% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (16 filings), option exercises (12 filings), shares withheld for taxes (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IONS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.